莎普愛思(603168.SH):董事胡正國減持期過半 累計減持22萬股
格隆匯9月29日丨莎普愛思(603168.SH)公佈,公司董事胡正國2020年6月6日減持股份計劃的減持時間過半,即自2020年7月1日至2020年9月28日期間,胡正國通過集中競價交易方式減持莎普愛思股份22萬股,佔莎普愛思總股本的0.0682%,佔計劃減持股份數量上限的8.0586%,本次減持計劃尚未實施完畢。
截至2020年9月28日,胡正國持有莎普愛思無限售條件流通股1070萬股,佔莎普愛思總股本的3.3169%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.